Digital quantitative assessment of PD-L1 using digital spatial profiling
The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays u...
Saved in:
| Published in: | Laboratory investigation Vol. 100; no. 10; pp. 1311 - 1317 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New York
Elsevier Inc
01.10.2020
Nature Publishing Group US Nature Publishing Group |
| Subjects: | |
| ISSN: | 0023-6837, 1530-0307, 1530-0307 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy.
Digital spatial profiling is a new high-plex technology with potential to multiplex hundreds of proteins on a single slide. Here the authors validate the digital aspect of the technology on a control tissue microarray with known amounts of PD-L1 expression to show it has quantitative capacity comparable to quantitative immunofluorescence. |
|---|---|
| AbstractList | The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy.The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy. The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy.Digital spatial profiling is a new high-plex technology with potential to multiplex hundreds of proteins on a single slide. Here the authors validate the digital aspect of the technology on a control tissue microarray with known amounts of PD-L1 expression to show it has quantitative capacity comparable to quantitative immunofluorescence. The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy. Digital spatial profiling is a new high-plex technology with potential to multiplex hundreds of proteins on a single slide. Here the authors validate the digital aspect of the technology on a control tissue microarray with known amounts of PD-L1 expression to show it has quantitative capacity comparable to quantitative immunofluorescence. The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA approved PD-L1 assay and one LDT assay and 3 quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various range of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using GeoMx DSP assay and readout on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy. Digital spatial profiling is a new high-plex technology with potential to multiplex hundreds of proteins on a single slide. Here the authors validate the digital aspect of the technology on a control tissue microarray with known amounts of PD-L1 expression to show it has quantitative capacity comparable to quantitative immunofluorescence. The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy. |
| Author | Gupta, Swati Martinez-Morilla, Sandra Zugazagoitia, Jon Fuhrman, Kit Rimm, David L. |
| AuthorAffiliation | 1 Department of Pathology, Yale University School of Medicine, New Haven, CT 2 Nanostring Technologies®, Seattle, WA 3 Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT |
| AuthorAffiliation_xml | – name: 1 Department of Pathology, Yale University School of Medicine, New Haven, CT – name: 3 Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT – name: 2 Nanostring Technologies®, Seattle, WA |
| Author_xml | – sequence: 1 givenname: Swati surname: Gupta fullname: Gupta, Swati organization: Department of Pathology, Yale University School of Medicine, New Haven, CT, US – sequence: 2 givenname: Jon surname: Zugazagoitia fullname: Zugazagoitia, Jon organization: Department of Pathology, Yale University School of Medicine, New Haven, CT, US – sequence: 3 givenname: Sandra surname: Martinez-Morilla fullname: Martinez-Morilla, Sandra organization: Department of Pathology, Yale University School of Medicine, New Haven, CT, US – sequence: 4 givenname: Kit surname: Fuhrman fullname: Fuhrman, Kit organization: Nanostring Technologies®, Seattle, WA, US – sequence: 5 givenname: David L. orcidid: 0000-0001-5820-4397 surname: Rimm fullname: Rimm, David L. email: david.rimm@yale.edu organization: Department of Pathology, Yale University School of Medicine, New Haven, CT, US |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32249818$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS3Uim4LH4ALisSFS6jHf-JESEioBVppJTjA2fI648VV1t7ayUp8e7xkC7SHPY3teb_R87xzchJiQEJeAX0HlLeXWQBXoqaM1lQwUctnZAGSlxun6oQsKGW8blquzsh5zneUghCNfE7OOGOia6FdkJtrv_ajGar7yYSxnEa_w8rkjDlvMIxVdNW363oJ1ZR9WFf9QZ63RVnqNkXnh9J5QU6dGTK-PNQL8uPzp-9XN_Xy65fbq4_L2krGxhocNtiBBWUUKtczZRiViq9aZrgr76xvVOOs7cFxJl0PABJUy0G0zUp0_IJ8mOdup9UGe1s8JjPobfIbk37paLx-3An-p17HnVaSMsGbMuDtYUCK9xPmUW98tjgMJmCcsma8bYSkQEWRvnkivYtTCuV7mgkluo52jBXV6_8d_bXysOQiULPApphzQqftn0XHvUE_aKB6H6ee49QlTr2PU8tCwhPyYfgxhs1MLtqwxvTP9DHo_QxhiW7nC5Stx2Cx9wntqPvoj9C_AZeww_I |
| CitedBy_id | crossref_primary_10_1136_jcp_2024_209766 crossref_primary_10_1631_jzus_B2200605 crossref_primary_10_3390_cancers14194923 crossref_primary_10_3390_cancers12092572 crossref_primary_10_1016_j_eururo_2023_11_008 crossref_primary_10_1038_s41571_021_00520_1 crossref_primary_10_3389_fonc_2022_890410 crossref_primary_10_1016_j_lungcan_2023_107230 crossref_primary_10_3389_fimmu_2022_920021 crossref_primary_10_1186_s42047_025_00177_5 crossref_primary_10_3390_cancers14153833 crossref_primary_10_1158_1078_0432_CCR_21_0343 crossref_primary_10_1158_1078_0432_CCR_24_2469 crossref_primary_10_3389_fimmu_2022_996721 crossref_primary_10_1136_jitc_2022_006234 crossref_primary_10_1007_s00259_024_06610_3 crossref_primary_10_1038_s41467_023_37806_0 crossref_primary_10_3390_cancers13010029 crossref_primary_10_1038_s41467_021_27723_5 crossref_primary_10_1158_1078_0432_CCR_24_0853 crossref_primary_10_1007_s00761_021_01070_y crossref_primary_10_1093_jnen_nlab122 crossref_primary_10_1007_s12035_022_03031_x crossref_primary_10_1016_j_ijbiomac_2024_129551 crossref_primary_10_1146_annurev_biodatasci_102523_103640 |
| Cites_doi | 10.1200/JCO.2015.63.7421 10.1038/s41598-017-17204-5 10.1136/jclinpath-2018-205362 10.1016/S0140-6736(15)01281-7 10.1158/1078-0432.CCR-19-0104 10.1038/modpathol.2017.59 10.1038/modpathol.2017.188 10.1158/1535-7163.MCT-14-0983 10.1056/NEJMoa1200694 10.1002/cncr.25747 10.1016/j.jtho.2017.11.112 10.1016/j.jtho.2016.11.2228 10.1158/1078-0432.CCR-16-2375 10.1016/j.jtho.2018.05.013 10.1056/NEJMoa1709937 10.1200/JCO.2017.74.3062 10.1001/jamaoncol.2017.0013 10.1126/science.aaa8172 10.1016/j.jtho.2017.11.123 10.1001/jamaoncol.2016.3015 10.1101/559021 |
| ContentType | Journal Article |
| Copyright | 2020 United States & Canadian Academy of Pathology The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2020 The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2020. |
| Copyright_xml | – notice: 2020 United States & Canadian Academy of Pathology – notice: The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2020 – notice: The Author(s), under exclusive licence to United States and Canadian Academy of Pathology 2020. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41374-020-0424-5 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Central Student MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1530-0307 |
| EndPage | 1317 |
| ExternalDocumentID | PMC7502436 32249818 10_1038_s41374_020_0424_5 S0023683722003531 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Breast Cancer Research Foundation (BCRF) grantid: BCRF-19-138 funderid: https://doi.org/10.13039/100001006 – fundername: NCI NIH HHS grantid: P50 CA196530 – fundername: NCI NIH HHS grantid: P30 CA016359 – fundername: NCATS NIH HHS grantid: UL1 TR001863 |
| GroupedDBID | --- -Q- -~X .55 .GJ 0R~ 1KJ 29L 2WC 36B 39C 3V. 4.4 53G 5GY 5RE 6I. 70F 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W AADWK AAFTH AANZL AAWBL AAXUO AAYFA AAYJO AAZLF ABAWZ ABCQX ABGIJ ABJNI ABLJU ABUWG ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACZOJ ADBBV ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEXYK AFFNX AFKRA AFOSN AFRAH AFSHS AGAYW AGEZK AGGBP AGHAI AHMBA AHPSJ AHSBF AILAN AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRAJ AMRJV AMYLF ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DU5 E3Z EBLON EBS EE. EIOEI EJD EMB F5P FDB FDQFY FEDTE FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P MVM NAO NQJWS NYICJ O9- OK1 P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL S10 SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 TSG TWZ UKHRP X7M Y6R YFH YKV YOC YQI YQT ZA5 ZGI ZXP AAHOK AALRI ADVLN AFJKZ AITUG AKRWK ALIPV PKN AAYWO AAYXX ACVFH ADCNI ADXHL AEUPX AFFHD AFPUW AIGII AKBMS AKYEP APXCP CITATION EFKBS PHGZM PHGZT PJZUB PPXIY PQGLB AGCQF CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 7XB 8FD 8FE 8FH 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c522t-1fe6e91c17a7e7fd27a20573b82a3f1c12d676fccd1f325fd111517831486b493 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000523949500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0023-6837 1530-0307 |
| IngestDate | Tue Nov 04 01:56:18 EST 2025 Sat Sep 27 22:07:30 EDT 2025 Mon Oct 06 16:56:19 EDT 2025 Mon Jul 21 06:02:15 EDT 2025 Sat Nov 29 01:48:22 EST 2025 Tue Nov 18 21:08:04 EST 2025 Fri Feb 21 02:38:04 EST 2025 Fri Feb 23 02:39:23 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | This article is made available under the Elsevier license. Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c522t-1fe6e91c17a7e7fd27a20573b82a3f1c12d676fccd1f325fd111517831486b493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 AUTHORS’ CONTRIBUTION DLR and SG conceived the study, supervised the analysis and revised the final version of the manuscript. SG and JZ selected the study specimens and carried out the GeoMx DSP data analysis. SG drafted the manuscript. KF performed the GeoMx DSP assay. SMM carried out fluorescent and chromogenic IHC assay. All authors have read and approved the final version of the manuscript. |
| ORCID | 0000-0001-5820-4397 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7502436 |
| PMID | 32249818 |
| PQID | 2474990922 |
| PQPubID | 25033 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7502436 proquest_miscellaneous_2386450104 proquest_journals_2474990922 pubmed_primary_32249818 crossref_citationtrail_10_1038_s41374_020_0424_5 crossref_primary_10_1038_s41374_020_0424_5 springer_journals_10_1038_s41374_020_0424_5 elsevier_sciencedirect_doi_10_1038_s41374_020_0424_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-01 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationSubtitle | Advancing the understanding of human and experimental disease |
| PublicationTitle | Laboratory investigation |
| PublicationTitleAbbrev | Lab Invest |
| PublicationTitleAlternate | Lab Invest |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Elsevier Inc – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | Merritt CR, Ong GT, Church S, Barker K, Geiss G, Hoang M, et al. High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods. bioRxiv. 2019. Herbst, Baas, Kim, Felip, Perez-Gracia, Han (bib2) 2016; 387 McDermott, Sosman, Sznol, Massard, Gordon, Hamid (bib4) 2016; 34 Brunnstrom, Johansson, Westbom-Fremer, Backman, Djureinovic, Patthey (bib17) 2017; 30 Antonia, Villegas, Daniel, Vicente, Murakami, Hui (bib1) 2017; 377 Patel, Kurzrock (bib5) 2015; 14 Brahmer, Tykodi, Chow, Hwu, Topalian, Hwu (bib6) 2012; 366 Toki, Merritt, Wong, Smithy, Kluger, Syrigos (bib19) 2019; 25 Gaule, Smithy, Toki, Rehman, Patell-Socha, Cougot (bib15) 2017; 3 Gadiot, Hooijkaas, Kaiser, van Tinteren, van Boven, Blank (bib7) 2011; 117 Tsao, Kerr, Kockx, Beasley, Borczuk, Botling (bib16) 2018; 13 . Ratcliffe, Sharpe, Midha, Barker, Scott, Scorer (bib13) 2017; 23 Hendry, Byrne, Wright, Young, Sturrock, Cooper (bib11) 2018; 13 Sharma, Allison (bib21) 2015; 348 Batenchuk, Albitar, Zerba, Sudarsanam, Chizhevsky, Jin (bib8) 2018; 71 Hirsch, McElhinny, Stanforth, Ranger-Moore, Jansson, Kulangara (bib14) 2017; 12 Rimm, Han, Taube, Yi, Bridge, Flieder (bib12) 2017; 3 Tretiakova, Fulton, Kocherginsky, Long, Ussakli, Antic (bib9) 2018; 31 Horn, Spigel, Vokes, Holgado, Ready, Steins (bib3) 2017; 35 Fujimoto, Sato, Uehara, Ishida, Fukuoka, Morimoto (bib10) 2018; 13 Bankhead, Loughrey, Fernandez, Dombrowski, McArt, Dunne (bib20) 2017; 7 Antonia, Villegas, Daniel, Vicente, Murakami, Hui (CR1) 2017; 377 Horn, Spigel, Vokes, Holgado, Ready, Steins (CR3) 2017; 35 Gaule, Smithy, Toki, Rehman, Patell-Socha, Cougot (CR15) 2017; 3 Patel, Kurzrock (CR5) 2015; 14 Tsao, Kerr, Kockx, Beasley, Borczuk, Botling (CR16) 2018; 13 CR18 Hendry, Byrne, Wright, Young, Sturrock, Cooper (CR11) 2018; 13 Gadiot, Hooijkaas, Kaiser, van Tinteren, van Boven, Blank (CR7) 2011; 117 Hirsch, McElhinny, Stanforth, Ranger-Moore, Jansson, Kulangara (CR14) 2017; 12 Toki, Merritt, Wong, Smithy, Kluger, Syrigos (CR19) 2019; 25 McDermott, Sosman, Sznol, Massard, Gordon, Hamid (CR4) 2016; 34 Tretiakova, Fulton, Kocherginsky, Long, Ussakli, Antic (CR9) 2018; 31 Fujimoto, Sato, Uehara, Ishida, Fukuoka, Morimoto (CR10) 2018; 13 Rimm, Han, Taube, Yi, Bridge, Flieder (CR12) 2017; 3 Bankhead, Loughrey, Fernandez, Dombrowski, McArt, Dunne (CR20) 2017; 7 Brunnstrom, Johansson, Westbom-Fremer, Backman, Djureinovic, Patthey (CR17) 2017; 30 Herbst, Baas, Kim, Felip, Perez-Gracia, Han (CR2) 2016; 387 Ratcliffe, Sharpe, Midha, Barker, Scott, Scorer (CR13) 2017; 23 Batenchuk, Albitar, Zerba, Sudarsanam, Chizhevsky, Jin (CR8) 2018; 71 Brahmer, Tykodi, Chow, Hwu, Topalian, Hwu (CR6) 2012; 366 Sharma, Allison (CR21) 2015; 348 Horn (10.1038/s41374-020-0424-5_bib3) 2017; 35 McDermott (10.1038/s41374-020-0424-5_bib4) 2016; 34 Bankhead (10.1038/s41374-020-0424-5_bib20) 2017; 7 Antonia (10.1038/s41374-020-0424-5_bib1) 2017; 377 Patel (10.1038/s41374-020-0424-5_bib5) 2015; 14 Tsao (10.1038/s41374-020-0424-5_bib16) 2018; 13 Tretiakova (10.1038/s41374-020-0424-5_bib9) 2018; 31 Batenchuk (10.1038/s41374-020-0424-5_bib8) 2018; 71 Hirsch (10.1038/s41374-020-0424-5_bib14) 2017; 12 Gaule (10.1038/s41374-020-0424-5_bib15) 2017; 3 Toki (10.1038/s41374-020-0424-5_bib19) 2019; 25 Fujimoto (10.1038/s41374-020-0424-5_bib10) 2018; 13 Brunnstrom (10.1038/s41374-020-0424-5_bib17) 2017; 30 Hendry (10.1038/s41374-020-0424-5_bib11) 2018; 13 Rimm (10.1038/s41374-020-0424-5_bib12) 2017; 3 10.1038/s41374-020-0424-5_bib18 Herbst (10.1038/s41374-020-0424-5_bib2) 2016; 387 Ratcliffe (10.1038/s41374-020-0424-5_bib13) 2017; 23 Sharma (10.1038/s41374-020-0424-5_bib21) 2015; 348 Brahmer (10.1038/s41374-020-0424-5_bib6) 2012; 366 Gadiot (10.1038/s41374-020-0424-5_bib7) 2011; 117 |
| References_xml | – volume: 366 start-page: 2455 year: 2012 end-page: 2465 ident: bib6 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N Engl J Med – volume: 25 start-page: 5503 year: 2019 ident: bib19 article-title: High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling publication-title: Clin Cancer Res – volume: 34 start-page: 833 year: 2016 end-page: 842 ident: bib4 article-title: Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study publication-title: J Clin Oncol – volume: 14 start-page: 847 year: 2015 end-page: 856 ident: bib5 article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy publication-title: Mol Cancer Ther – volume: 3 start-page: 256 year: 2017 ident: bib15 article-title: A quantitative comparison of antibodies to programmed cell death 1 ligand 1 publication-title: JAMA Oncol – volume: 13 start-page: 367 year: 2018 ident: bib11 article-title: Comparison of four PD-L1 immunohistochemical assays in lung cancer publication-title: J Thorac Oncol – volume: 3 start-page: 1051 year: 2017 end-page: 1058 ident: bib12 article-title: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer publication-title: JAMA Oncol – volume: 13 start-page: 377 year: 2018 ident: bib10 article-title: Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer publication-title: J Thorac Oncol – reference: Merritt CR, Ong GT, Church S, Barker K, Geiss G, Hoang M, et al. High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods. bioRxiv. 2019. – volume: 12 start-page: 208 year: 2017 ident: bib14 article-title: PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J Thorac Oncol – volume: 23 start-page: 3585 year: 2017 ident: bib13 article-title: Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer publication-title: Clin Cancer Res – reference: . – volume: 35 start-page: 3924 year: 2017 ident: bib3 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol – volume: 7 year: 2017 ident: bib20 article-title: QuPath: open source software for digital pathology image analysis publication-title: Sci Rep. – volume: 71 start-page: 1078 year: 2018 ident: bib8 article-title: A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies publication-title: J Clin Pathol – volume: 13 start-page: 1302 year: 2018 ident: bib16 article-title: PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project publication-title: J Thorac Oncol – volume: 30 start-page: 1411 year: 2017 ident: bib17 article-title: PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability publication-title: Mod Pathol. – volume: 31 start-page: 623 year: 2018 ident: bib9 article-title: Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression publication-title: Mod Pathol. – volume: 117 start-page: 2192 year: 2011 end-page: 2201 ident: bib7 article-title: Overall survival and PD-L1 expression in metastasized malignant melanoma publication-title: Cancer. – volume: 377 start-page: 1919 year: 2017 ident: bib1 article-title: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer publication-title: N Engl J Med – volume: 387 start-page: 1540 year: 2016 ident: bib2 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet. – volume: 348 start-page: 56 year: 2015 end-page: 61 ident: bib21 article-title: The future of immune checkpoint therapy publication-title: Science – volume: 34 start-page: 833 year: 2016 end-page: 42 ident: CR4 article-title: Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.7421 – volume: 7 year: 2017 ident: CR20 article-title: QuPath: open source software for digital pathology image analysis publication-title: Sci Rep. doi: 10.1038/s41598-017-17204-5 – volume: 71 start-page: 1078 year: 2018 end-page: 83. ident: CR8 article-title: A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies publication-title: J Clin Pathol doi: 10.1136/jclinpath-2018-205362 – ident: CR18 – volume: 387 start-page: 1540 year: 2016 end-page: 50. ident: CR2 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet. doi: 10.1016/S0140-6736(15)01281-7 – volume: 25 start-page: 5503 year: 2019 end-page: 12. ident: CR19 article-title: High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0104 – volume: 30 start-page: 1411 year: 2017 end-page: 21. ident: CR17 article-title: PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability publication-title: Mod Pathol. doi: 10.1038/modpathol.2017.59 – volume: 31 start-page: 623 year: 2018 end-page: 32. ident: CR9 article-title: Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression publication-title: Mod Pathol. doi: 10.1038/modpathol.2017.188 – volume: 14 start-page: 847 year: 2015 end-page: 56 ident: CR5 article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 – volume: 366 start-page: 2455 year: 2012 end-page: 65 ident: CR6 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 – volume: 117 start-page: 2192 year: 2011 end-page: 201 ident: CR7 article-title: Overall survival and PD-L1 expression in metastasized malignant melanoma publication-title: Cancer. doi: 10.1002/cncr.25747 – volume: 13 start-page: 367 year: 2018 end-page: 76. ident: CR11 article-title: Comparison of four PD-L1 immunohistochemical assays in lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.11.112 – volume: 12 start-page: 208 year: 2017 end-page: 22. ident: CR14 article-title: PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.11.2228 – volume: 23 start-page: 3585 year: 2017 end-page: 91. ident: CR13 article-title: Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2375 – volume: 13 start-page: 1302 year: 2018 end-page: 11. ident: CR16 article-title: PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.05.013 – volume: 377 start-page: 1919 year: 2017 end-page: 29. ident: CR1 article-title: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1709937 – volume: 35 start-page: 3924 year: 2017 end-page: 33. ident: CR3 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.3062 – volume: 3 start-page: 1051 year: 2017 end-page: 8 ident: CR12 article-title: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.0013 – volume: 348 start-page: 56 year: 2015 end-page: 61 ident: CR21 article-title: The future of immune checkpoint therapy publication-title: Science doi: 10.1126/science.aaa8172 – volume: 13 start-page: 377 year: 2018 end-page: 86. ident: CR10 article-title: Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.11.123 – volume: 3 start-page: 256 year: 2017 end-page: 9. ident: CR15 article-title: A quantitative comparison of antibodies to programmed cell death 1 ligand 1 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.3015 – ident: 10.1038/s41374-020-0424-5_bib18 doi: 10.1101/559021 – volume: 387 start-page: 1540 year: 2016 ident: 10.1038/s41374-020-0424-5_bib2 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet. doi: 10.1016/S0140-6736(15)01281-7 – volume: 13 start-page: 377 year: 2018 ident: 10.1038/s41374-020-0424-5_bib10 article-title: Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.11.123 – volume: 3 start-page: 256 year: 2017 ident: 10.1038/s41374-020-0424-5_bib15 article-title: A quantitative comparison of antibodies to programmed cell death 1 ligand 1 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.3015 – volume: 7 year: 2017 ident: 10.1038/s41374-020-0424-5_bib20 article-title: QuPath: open source software for digital pathology image analysis publication-title: Sci Rep. doi: 10.1038/s41598-017-17204-5 – volume: 34 start-page: 833 year: 2016 ident: 10.1038/s41374-020-0424-5_bib4 article-title: Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.7421 – volume: 12 start-page: 208 year: 2017 ident: 10.1038/s41374-020-0424-5_bib14 article-title: PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.11.2228 – volume: 35 start-page: 3924 year: 2017 ident: 10.1038/s41374-020-0424-5_bib3 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.3062 – volume: 13 start-page: 1302 year: 2018 ident: 10.1038/s41374-020-0424-5_bib16 article-title: PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.05.013 – volume: 377 start-page: 1919 year: 2017 ident: 10.1038/s41374-020-0424-5_bib1 article-title: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1709937 – volume: 71 start-page: 1078 year: 2018 ident: 10.1038/s41374-020-0424-5_bib8 article-title: A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies publication-title: J Clin Pathol doi: 10.1136/jclinpath-2018-205362 – volume: 14 start-page: 847 year: 2015 ident: 10.1038/s41374-020-0424-5_bib5 article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 – volume: 348 start-page: 56 year: 2015 ident: 10.1038/s41374-020-0424-5_bib21 article-title: The future of immune checkpoint therapy publication-title: Science doi: 10.1126/science.aaa8172 – volume: 3 start-page: 1051 year: 2017 ident: 10.1038/s41374-020-0424-5_bib12 article-title: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.0013 – volume: 366 start-page: 2455 year: 2012 ident: 10.1038/s41374-020-0424-5_bib6 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 – volume: 25 start-page: 5503 year: 2019 ident: 10.1038/s41374-020-0424-5_bib19 article-title: High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0104 – volume: 117 start-page: 2192 year: 2011 ident: 10.1038/s41374-020-0424-5_bib7 article-title: Overall survival and PD-L1 expression in metastasized malignant melanoma publication-title: Cancer. doi: 10.1002/cncr.25747 – volume: 31 start-page: 623 year: 2018 ident: 10.1038/s41374-020-0424-5_bib9 article-title: Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression publication-title: Mod Pathol. doi: 10.1038/modpathol.2017.188 – volume: 30 start-page: 1411 year: 2017 ident: 10.1038/s41374-020-0424-5_bib17 article-title: PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability publication-title: Mod Pathol. doi: 10.1038/modpathol.2017.59 – volume: 13 start-page: 367 year: 2018 ident: 10.1038/s41374-020-0424-5_bib11 article-title: Comparison of four PD-L1 immunohistochemical assays in lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.11.112 – volume: 23 start-page: 3585 year: 2017 ident: 10.1038/s41374-020-0424-5_bib13 article-title: Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2375 |
| SSID | ssj0014465 |
| Score | 2.4638069 |
| Snippet | The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive... |
| SourceID | pubmedcentral proquest pubmed crossref springer elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1311 |
| SubjectTerms | 13/105 13/51 631/61/32 692/53/2423 82/1 82/80 Antibodies Apoptosis Assaying B7-H1 Antigen - analysis B7-H1 Antigen - metabolism Biomarkers - analysis Biomarkers - metabolism Biotechnology Cell Line Correlation analysis Diagnostic systems FDA approval Fluorescence Humans Immune checkpoint Immune system Immunofluorescence Immunohistochemistry Immunohistochemistry - methods Immunohistochemistry - statistics & numerical data Immunotherapy L1 protein Laboratory Medicine Medicine Medicine & Public Health New technology Pathology PD-1 protein PD-L1 protein Protein Array Analysis - methods Protein Array Analysis - statistics & numerical data Proteins Reproducibility of Results Standardization Tissue Array Analysis - methods Tissue Array Analysis - statistics & numerical data Tissues Tumor cells |
| Title | Digital quantitative assessment of PD-L1 using digital spatial profiling |
| URI | https://dx.doi.org/10.1038/s41374-020-0424-5 https://link.springer.com/article/10.1038/s41374-020-0424-5 https://www.ncbi.nlm.nih.gov/pubmed/32249818 https://www.proquest.com/docview/2474990922 https://www.proquest.com/docview/2386450104 https://pubmed.ncbi.nlm.nih.gov/PMC7502436 |
| Volume | 100 |
| WOSCitedRecordID | wos000523949500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1530-0307 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0014465 issn: 0023-6837 databaseCode: M7P dateStart: 20000101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1530-0307 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0014465 issn: 0023-6837 databaseCode: 7X7 dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1530-0307 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0014465 issn: 0023-6837 databaseCode: BENPR dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1530-0307 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0014465 issn: 0023-6837 databaseCode: 8C1 dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7apJRc-m7iNl1c6KnFxHrYsk6lzYMc2mUpLexNyLKULgRvEu_m92ckyw5pyF56scEagcQ8NKMZzwfwiWgubF6gphGBAYoxaAdlXWS5lUbqhllrXQCbENNpNZ_LWbxw62JZ5WATg6FulsbfkR9QLtA5zyWlXy8uM48a5bOrEULjMWx72Gwv52I-BlyhGVhf4sGyEiOxIavJqoMOjbfgmQ-efPIvKx46l-77nffLJ__JoYaj6eT5_27qBTyLTmn6rZeil_DItq_g6c-Ydn8Np0eLMw8ukl6udRv-SkMbmeqxqWe6dOnsKPtBUl9Gf5Y2kbzz5dr47oHBceQN_Dk5_n14mkUIhsygY7bKiLOllcQQoYUVrqFCU99Csa6oZg6_06YUpTOmIY7RwjVoOgsiKoZRVllzyd7CVrts7R6kzDBSOi1cbjWvCyZrJzHYs7w2ed5ULIF8YIAysT-5h8k4VyFPzirV80whz5TnmSoS-DxOueibc2wi5gNXVfQueq9B4eGxadr-wDoV1btTt3xL4OM4jIrpsy26tcs10rCq5IUPdxPY7QVmXCRaUS7RVUpA3BGlkcA3_b470i7-hubf6OFRzsoEvgxCd7usBzfxbvMm3sMO9ZoQahT3YWt1tbYf4Im5Xi26q0nQqfCs8Fkdkglsfz-ezn5NfKHs7AbfvSnM |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBQEX3tBAASPBBWQ1sZ04OSCEulRbdbvqoUi9Gcexy0pVtm12QfwpfiNj51GVqnvrgVOkeCzZ8TevzHgG4F2ihbRxipyWSHRQjEE5WJQpjW1hCl1xa60LzSbkdJofHRUHa_Cnvwvj0yp7mRgEdTU3_h_5FhMSjfO4YOzz6Rn1XaN8dLVvodHCYs_-_oUuW_Npd4Tn-56xna-H22PadRWgBm2NBU2czWyRmERqaaWrmNTMVwUsc6a5w_esymTmjKkSx1nqKpQGaSJzjo5DVgpffAlF_i3BGfdclG8PKSWh-FibUsJphp5fH0Xl-VaDykIK6p01H2yk6XV68KqdezVd85-YbVCFOw_-t4_4EO53Rjf50nLJI1iz9WO4s9-lFTyB8Wh27JunkLOlrsOtO9QBRA9FS8nckYMRnSTEXxM4JlVH3vh0dHy2jc9x5Cl8u5F9PIP1el7bDSDc8CRzWrrYalGmvChdgc6sFaWJ4yrnEcT9gSvT1V_3bUBOVMgD4LlqMaIQI8pjRKURfBimnLbFR1YRix5FqrOeWqtIoXJcNW2zh4rqxFejLnASwdthGAWPjybp2s6XSMPzTKTenY_geQvQYZGoJUSBpmAE8hJ0BwJf1PzySD37EYqbowXLBM8i-NiD_GJZ127ixepNvIG748P9iZrsTvdewj3muTDkY27C-uJ8aV_BbfNzMWvOXwd-JvD9prH_F0IngLk |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VW1Rx4U0JFAgSXEDWJrYTJwdUFbarVi2rFQKpN-M4dlkJZdtmF8Rf66_rOHFSlap764FTpHgs2fE3r8x4BuBtrLgwUYKcFgt0ULRGOZgXCYlMrnNVMmOMbZpNiMkkOzrKp2tw3t2FcWmVnUxsBHU51-4f-ZBygcZ5lFM6tD4tYjoab5-cEtdBykVau3YaLUQOzN8_6L7VH_dHeNbvKB3vfvu8R3yHAaLR7liQ2JrU5LGOhRJG2JIKRV2FwCKjill8T8tUpFbrMraMJrZEyZDEImPoRKQFd4WYUPyvC4ZOzwDWP-1Opl_7GIYrRdYmmDCSoh_YxVRZNqxRdQhOnOvmQo8kuUkrXrd6rydv_hPBbRTj-P7__EkfwD1vjoc7Lf88hDVTPYKNLz7h4DHsjWbHrq1KeLpUVXMfD7VDqPpypuHchtMROYxDd4HgOCw9ee0S1fHZtkTHkSfw_Vb28RQG1bwyzyBkmsWpVcJGRvEiYXlhc3RzDS90FJUZCyDqDl9qX5ndNQj5JZsMAZbJFi8S8SIdXmQSwPt-yklblmQVMe8QJb1d1dpLEtXmqmlbHWykF2y1vMRMAG_6YRRJLs6kKjNfIg3LUp44Rz-AzRas_SJRf_AcjcQAxBUY9wSu3PnVkWr2syl7jrYt5SwN4EMH-Mtl3biJ56s38Ro2EPLycH9y8ALuUseQTaLmFgwWZ0vzEu7o34tZffbKM3cIP24b_BfK-YsX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Digital+quantitative+assessment+of+PD-L1+using+digital+spatial+profiling&rft.jtitle=Laboratory+investigation&rft.au=Gupta%2C+Swati&rft.au=Zugazagoitia%2C+Jon&rft.au=Martinez-Morilla%2C+Sandra&rft.au=Fuhrman%2C+Kit&rft.date=2020-10-01&rft.issn=1530-0307&rft.eissn=1530-0307&rft.volume=100&rft.issue=10&rft.spage=1311&rft_id=info:doi/10.1038%2Fs41374-020-0424-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0023-6837&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0023-6837&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0023-6837&client=summon |